Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Core Scientific, Inc. (NASDAQ: CORZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Core Scientific operates in data processing, hosting and related services, with business segments that include digital asset self-mining, digital asset hosted mining and high-density colocation. Its SEC filings offer detailed insight into how these activities are structured, the associated risks and the company’s capital markets activity.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for narrative and quantitative information about Core Scientific’s digital infrastructure, revenue mix among self-mining, hosted mining and high-density colocation, and its stated transition toward artificial intelligence-related workloads. These reports also describe facility locations across several U.S. states and discuss operational dependencies such as access to significant electric power resources.
Current reports on Form 8-K are particularly important for tracking material events. In 2025, Core Scientific filed multiple 8-Ks regarding an Agreement and Plan of Merger with CoreWeave, Inc., the scheduling of a special meeting of stockholders, supplemental proxy disclosures, and the final voting results. A Form 8-K dated October 30, 2025 reports that stockholders did not approve the merger proposal and that the Merger Agreement was terminated, while a Form 8-K dated October 31, 2025 provides detailed vote counts.
These filings also contain extensive risk factor discussions, including the company’s ability to earn digital assets profitably, attract high-density colocation customers, secure power resources, and navigate regulatory developments affecting digital assets and high-density computing. Stock Titan enhances this information with AI-powered summaries that explain the key points of lengthy filings, highlight notable changes across reporting periods and surface items such as insider-related disclosures reported on Form 4 when available. Real-time updates from EDGAR help users monitor new CORZ filings, while AI-generated overviews make complex documents more accessible to a broad range of investors.
Core Scientific, Inc. director Rozov Yadin reported an award of 18,575 shares of common stock on February 4, 2026, coded as an acquisition at a price of $0 per share. This reflects a grant rather than an open-market purchase.
The award represents a restricted stock unit grant that will vest in full on February 3, 2027, if Yadin continues to serve as a non-employee director through that date. After this grant, Yadin beneficially owns 454,162 shares of Core Scientific common stock in direct ownership.
Core Scientific director Eric Stanton Weiss received a new equity grant. On February 4, 2026, he was awarded 18,575 shares of Core Scientific common stock at a price of $0 per share, bringing his directly held stake to 245,262 shares.
The award is structured as restricted stock units that will vest in full on February 3, 2027, provided Weiss continues to serve the company as a non-employee director through that date.
Core Scientific, Inc. CEO and director reported an amendment to a prior insider transaction report. On January 29, 2026, 274,554 shares of common stock were withheld at $18.79 per share to cover tax obligations from vesting restricted stock units. After this withholding, the reporting person beneficially owned 4,131,150 shares directly. The amendment corrects an earlier filing that had inadvertently reported 274,404 shares withheld on January 23, 2026.
Core Scientific CEO Adam Taylor reported a tax-related share withholding. On 01/23/2026, 274,404 shares of Core Scientific common stock were withheld at a price of $18.79 per share to cover withholding tax obligations tied to the vesting of restricted stock units.
After this automatic withholding, Taylor directly beneficially owned 4,131,300 shares. The transaction is coded "F," indicating it was associated with equity award vesting rather than an open-market sale.
Two Seas Capital and related reporting persons filed an amended ownership report for Core Scientific, Inc., disclosing beneficial ownership of 22,472,467 shares of common stock, or about 7.2% of the company. This total includes 313,646 shares issuable upon exercise of warrants and options to purchase 5,077,600 shares at an exercise price of $17 that expire on February 20, 2026. The position is held through various funds and accounts that have delegated sole voting and investment power to Two Seas Capital.
The filing states the securities were acquired for investment purposes in the ordinary course of business because they were viewed as an attractive opportunity. The reporting persons may engage with Core Scientific’s management, board, other shareholders, and market participants on topics such as business strategy, capital allocation, governance, and environmental and social matters. They also indicate they may increase or decrease their position or use derivatives and hedging strategies to adjust their economic exposure over time.
The Vanguard Group filed an amended Schedule 13G reporting a significant passive ownership stake in Core Scientific Inc. common stock. As of 12/31/2025, Vanguard reported beneficial ownership of 33,960,320 shares, representing 10.95% of the outstanding common stock. Vanguard reported 0 shares with sole voting power and 2,133,911 shares with shared voting power, while holding sole dispositive power over 31,476,399 shares and shared dispositive power over 2,483,921 shares. The filing classifies Vanguard as an investment adviser and states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific. Vanguard notes that its clients have rights to dividends and sale proceeds, but no single other person has an interest in more than 5% of the class.
Core Scientific (CORZ) reported an insider transaction on a Form 4. A director purchased 30,000 Tranche 1 Warrants on 11/12/2025, coded “P” for a purchase.
The weighted average purchase price was $9.948 per warrant, with multiple trades in a $9.85–$10.11 range. Each whole warrant is exercisable for one share of common stock at an exercise price of $6.81 per share, subject to adjustments.
The warrants are listed as exercisable beginning 01/23/2024 and expire 01/23/2027. Following the reported transactions, the reporting person beneficially owned 30,000 derivative securities, held directly.
Core Scientific, Inc. (CORZ) director reported a Form 4 purchase. On 11/04/2025, the reporting person bought 5,000 shares of common stock (transaction code P) at $21.50 per share. Following this transaction, the filer beneficially owned 226,687 shares, held as direct ownership.
Core Scientific (CORZ) stockholders rejected the proposed merger with CoreWeave, and the company terminated the Merger Agreement effective October 30, 2025. The deal would have merged a CoreWeave subsidiary into Core Scientific, making Core Scientific a wholly owned subsidiary of CoreWeave.
Turnout was high: 245,792,464 shares were present or represented, equal to approximately 79.97% of voting power as of the record date. The principal proposal to adopt the Merger Agreement received 20,752,327 votes For, 203,451,498 Against, and 21,588,639 Abstain. A related proposal received 10,019,439 For, 230,070,106 Against, and 5,702,921 Abstain. Shares outstanding were 307,355,193 as of September 19, 2025.
Core Scientific, Inc. filed an 8-K announcing an investor presentation that representatives intend to use with investors and analysts on or after October 30, 2025. The presentation is furnished as Exhibit 99.1 under Item 7.01 and is expressly deemed “furnished,” not “filed,” which means it is not subject to Section 18 liabilities and is not incorporated into other filings unless specifically referenced.
The filing also lists the company’s Nasdaq‑traded securities, including common stock (CORZ) and two warrant classes (CORZW and CORZZ) with exercise prices of $6.81 and $0.01 per share, respectively.